Antimicrobials
Fidaxomicin

Fidaxomicin

Restricted

None
None

Spectrum of Activity

Dosing

General Information

C. difficile Infection (CDI)

Restrictions:

  • A second or subsequent recurrence following treatment with oral vancomycin; or
  • Treatment failure with oral vancomycin for the current CDI episode; or
  • An intolerance or contraindication to oral vancomycin

Re-treatment Criteria:

  • Re-treatment with fidaxomicin will only be considered for an early relapse occurring within 8 weeks of the start of the most recent fidaxomicin course

Clinical Notes:

  1. Treatment failure is defined as 14 days of vancomycin therapy without acceptable clinical improvement
  2. Intolerant is defined as demonstrating serious adverse effects to treatments. The nature of intolerance(s) must be clearly documented

Claim Notes:

  • Should be prescribed by, or in consultation with, an infectious disease specialist/medical microbiologist (preferred) or an internist (if infectious disease or medical microbiology consult is not available)
  • Requests will be approved for 200mg twice a day for 10 days

Requires Special Authorization for PEI Pharmacare

  • GI disturbance
  • Cytopenias
  • Hypersensitivity: facial, tongue or throat swelling

Consult Infectious Disease

Antimicrobial class: Specialized anti-C. difficile macrocyclic agent

Pregnancy category: B

Biliary penetration: None

CSF penetration: None

Lung penetration: None

Urine penetration: None